Discussion
sexual dysfunction, breast cancer
URINARY TRACT INFECTIONS, COMPLICATIONS, BREAST CANCER
In this RCT including survivors of breast cancer with GSM undergoing treatment with aromatase inhibitors, the subjective and objective outcomes of most participants in both groups improved in symptom severity, sexuality, and vaginal tissue characteristics at the 6-month follow-up . However, there were no differences in the mean improvement between CLT and SLT groups.Our results suggest that the use of vaginal laser treatment was not effective and was significantly less tolerated than the sham treatment. Nonetheless, since an overall improvement of variables regardless of arm was observed, further studies are needed to determine whether one can attribute overall improvements to the FLT alone or to a placebo effect related to the participating in a trial with an experimental therapy.The scarcity safe options for sexual dysfunction in survivors of breast cancerRemarkably, vaginal laser treatment appears to be safe, with only mild AEs, such as spotting or vaginal itching, which may be present in approximately 45% of the patients during 5 sessions of treatment. Moderate complications, such as urinary tract infections, were observed in approximately 10% of patients, and no participants reported severe AEs. Moreover, tolerance according to a Likert Scale showed that CLT was a well-tolerated treatment but was significantly worse than SLT.In this study, many objective outcomes were assessed to provide objectiveness in the evaluation of efficacy. Evaluation of safety and tolerance as well as adherence to treatment were meticulously assessed. Some of the possible biases found in previous RCTs have been taken into consideration in this trial.